探索C5抑制治疗在硬皮病肾危象所致血栓性微血管病中的作用——文献综述
本系统综述检索至2022年12月的文献,纳入17例接受C5抑制剂依库珠单抗治疗的硬皮病肾危象患者,其中64.7%合用ACE-I,82.3%报告肾脏或血液学临床改善,作者认为这些发现应推动在更大规模SRC-TMA患者队列中开展检测。
要点
- 17例硬皮病肾危象患者均接受依库珠单抗治疗,14/17(82.3%)报告肾脏或血液学临床改善。
- 合并用药包括ACE-I 11/17(64.7%)、血浆置换9/17(52.9%)、糖皮质激素5/17(29.4%)。
- 11/17(64.7%)患者需要肾脏替代治疗。
核心结论
- 作者认为这些发现应推动在更大规模的SRC-TMA患者队列中开展检测,以确定ACE-I联合依库珠单抗的积极治疗能否针对SRC-TMA涉及的多种内皮、炎症和免疫机制并改善患者结局。
研究设计与样本
- 系统综述,检索MEDLINE等数据库自建库至2022年12月,使用MeSH词「scleroderma」「scleroderma renal crisis」「Eculizumab」检索,纳入报告依库珠单抗(联合或不联合ACE-I)治疗系统性硬化症相关硬皮病肾危象的病例报告、病例系列和观察性研究,最终纳入17例患者。
主要发现
- 17例患者均接受依库珠单抗治疗,14/17(82.3%)报告肾脏或血液学临床改善。
- ACE-I使用率为11/17(64.7%),血浆置换9/17(52.9%),糖皮质激素5/17(29.4%),环磷酰胺3/17(17.6%),钙通道阻滞剂3/17(17.6%),利妥昔单抗3/17(17.6%)。
- 肾脏替代治疗需求为11/17(64.7%)。
关键数值与推荐
- 依库珠单抗为针对补体C5的单克隆抗体。
- 临床改善定义为肾脏或血液学改善,14/17(82.3%)患者达到。
临床怎么用
- 作者建议在更大规模SRC-TMA患者队列中开展检测,以明确ACE-I联合依库珠单抗的积极治疗能否针对SRC-TMA涉及的内皮、炎症和免疫机制并改善结局。
局限性
- 作者指出这些发现应推动在更大规模SRC-TMA患者队列中开展检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathogenesis of scleroderma renal crisis (SRC) remains poorly understood but a growing body of evidence suggests that activation of the complement system may be involved in the disease. Recent studies have shown that Eculizumab (monoclonal antibody directed against the complement component C5) is effective in treating patients with SRC who present with symptoms of thrombotic microangiopathy (SRC-TMA). OBJECTIVES: In this study, we conducted a systematic review to characterize the published experience of the presentation and outcome of patients with SRC who were treated with C5 inhibitor, Eculizumab. METHODS: A literature search was conducted from inception to December 2022 using Medical Subject Headings (MeSH) terms for 'scleroderma', 'scleroderma renal crisis, and 'Eculizumab'. We included case reports, case series, and observational studies which reported the use of Eculizumab with or without Angiotensin-converting enzyme inhibitors (ACE-I) for the treatment of scleroderma renal crisis (SRC) in patients with systemic sclerosis. RESULTS: The study included 17 patients, all of whom were treated with Eculizumab. Additionally, the use of ACE-I was reported in 11/17 (64.7%) patients. Further, plasmapheresis was used in 9/17 (52.9%), steroids in 5/17 (29.4%), cyclophosphamide in 3/17 (17.6%), calcium channel blockers in 3/17 (17.6%), and Rituximab in 3/17 (17.6%) patients. Renal replacement therapy was required in 11/17 (64.7%) patients. 14/17 patients (82.3%) were reported to have clinical (renal or hematologic) improvement with Eculizumab therapy (Table 1). CONCLUSION: These findings should prompt testing on a larger cohort of SRC-TMA patients. This would help us determine whether aggressive treatment combining ACE-I and Eculizumab can target the various underlying endothelial, inflammatory, and immunologic mechanisms involved in SRC-TMA, and improve patient outcomes.
引用
- Farrukh L, Steen VD, Shapiro L, et al. Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy - A Review of Literature. Semin Arthritis Rheum. 2023. PMID: 37689027. doi:10.1016/j.semarthrit.2023.152256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。